01 — Platform
Microalgae Platform
A proprietary microalgae production platform engineered for high-purity EPA development at scale. Renewable, traceable, and biologically optimized.
- Proprietary cultivation
- High-purity EPA
- Scalable & sustainable
Scientific Advantage
Where nature meets advanced therapeutics
Three converging disciplines — microalgae biology, polar lipid chemistry, and cannabinoid research — engineered into one therapeutic platform.
Scientific Advantage
Where nature meets advanced therapeutics
Three converging disciplines — microalgae biology, polar lipid chemistry, and cannabinoid research — engineered into one therapeutic platform.
02 — Innovation
EPA Innovation
EPA-only formulations with highly polar lipid architecture for superior bioavailability. Non-fish derived. Designed for therapeutic precision.
- EPA-only formulation
- Highly polar lipids
- Therapeutic-grade purity
03 — Synergy
Cannabinoid Synergy
Research-driven synergy between EPA and cannabinoid pathways — investigating enhanced functionality, improved signaling, and therapeutic optimization.
- Pathway synergy
- Signaling research
- Therapeutic optimization
Research & Evidence
Peer-reviewed. Institutionally rigorous.
Lipid Science
Polar EPA bioavailability vs. conventional fish-derived omega-3
Comparative pharmacokinetic review · 2024→
Neuroscience
EPA modulation of neuronal membrane fluidity in cortical models
Preclinical research summary · 2023→
Cannabinoid
Endocannabinoid–EPA signaling: a synergistic pathway hypothesis
Mechanistic review · 2024→